AnaptysBio Inc Stock
Price
Target price
€49.53
€49.53
-0.140%
-0.07
-0.140%
€65.03
12.08.26 / Frankfurt
WKN: A2AJ8C / Symbol: ANAB / Name: AnaptysBio / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
AnaptysBio Inc Stock
AnaptysBio Inc shows a slight decrease today, losing -€0.070 (-0.140%) compared to yesterday.
The stock is an absolute favorite of our community with 23 Buy predictions and no Sell predictions.
With a target price of 65 € there is a positive potential of 31.23% for AnaptysBio Inc compared to the current price of 49.53 €.
So far the community has only identified positive things for AnaptysBio Inc stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of AnaptysBio Inc in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
B****
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of AnaptysBio Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| AnaptysBio Inc | -0.140% | 4.692% | -14.603% | 191.353% | 15.186% | 187.965% | 147.650% |
| Ocuphire Pharma Inc. | 2.520% | 4.348% | -2.890% | 269.231% | 99.762% | -13.625% | -20.755% |
| NanoViricides Inc. | -1.710% | -8.000% | -12.214% | -11.538% | 23.656% | -1.709% | -64.018% |
| Actinium Pharmaceuticals Inc. | 1.160% | 10.015% | -13.139% | -45.161% | -40.845% | -87.795% | -87.018% |
Comments
AnaptysBio (ANAB) had its "buy" rating reaffirmed by HC Wainwright. They now have a $95.00 price target on the stock.
Show more
Ratings data for ANAB provided by MarketBeat
AnaptysBio (ANAB) had its "buy" rating reaffirmed by UBS Group AG.
Show more
Ratings data for ANAB provided by MarketBeat
AnaptysBio (ANAB) was given a new $85.00 price target by Leerink Partners. They now have an "outperform" rating on the stock.
Show more
Ratings data for ANAB provided by MarketBeat